It remains unclear whether the decongestive effects of acetazolamide differ across the spectrum of left ventricular ejection fraction (LVEF).
The Acetazolamide in Decompensated heart failure with Volume OveRload (ADVOR) trial is designed to test the hypothesis that the carbonic anhydrase inhibitor acetazolamide, a potent inhibitor of proximal tubular sodium reabsorption, improves decongestion when combined with loop diuretic therapy in AHF, potentially leading to better clinical
Aug 27, 2022 · Mullens W, Verbrugge FH, Nijst P, et al
The ADVOR trial was a randomized, double-blind, placebo-controlled trial that tested the hypothesis that intravenous ACTZ would improve decongestion when